Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-08EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
The European Medicines Agency authorised Scemblix (asciminib hydrochloride) for chronic myeloid leukemia (BCR-ABL positive) and granted orph…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
An ongoing clinical trial investigating muscle dysfunction in patients with hematologic diseases referred for stem cell transplantation.
-
FDA approval · 2025-11-25FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor [Phase 2]
Phase 2 clinical trial update evaluating post-transplantation benadamustine and cyclophosphamide in high-risk myeloid malignancies with part…
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (Dr. Reddy's Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' generic nilotinib under an Original Application (ANDA). It is indicated for chronic myeloid leukemia …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (AvKARE)
FDA approved AvKARE's nilotinib original application, authorizing a generic version of nilotinib for leukemia indications.
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic nilotinib product. The generic is intended to treat certain Philadel…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase [Phase 2]
This Phase 2 clinical trial is evaluating the safety and efficacy of sequencing ponatinib followed by imatinib in patients with chronic-phas…
-
FDA approval · 2025-11-14FDA Approved: DANZITEN — Supplemental Application (Azurity Pharmaceuticals, Inc.)
FDA action on a supplemental application for DANZITEN (nilotinib) from Azurity Pharmaceuticals, Inc.
-
EMA approval · 2025-11-12EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited
The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphom…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer [Phase 1]
A Phase 1 trial evaluating natural killer cell therapy in combination with Interleukin-2 and the TGF-beta receptor I inhibitor vactosertib f…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine [Phase 1]
A Phase 1 clinical trial evaluating a haploidentical bone marrow transplant using post-transplant cyclophosphamide and bendamustine has comp…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg [Phase 1]
Phase 1 dose-calibration study comparing IkT-001Pro to imatinib 400 mg in chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Personalized NK Cell Therapy in CBT [Phase 2]
A Phase 2 trial from MD Anderson is evaluating personalized NK cell therapy across several hematologic cancers. The study is currently recru…
-
FDA approval · 2025-11-06FDA Approved: DASATINIB — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic version of dasatinib (DASATINIB) from Alembic Pharmaceuticals Limited under an Original Application. The approval mak…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL [Phase 1]
HQP1351 is being investigated in a Phase 1 trial for patients with refractory chronic myeloid leukemia and Philadelphia chromosome-positive …
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion [NA]
Clinical trial update from Baylor College of Medicine reports results for haploidentical hematopoietic cell transplantation using TCR alpha/…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial evaluating asciminib monotherapy with dose escalation for first- and second-line chronic myeloid leukemia is active but not re…
-
FDA approval · 2025-10-02FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis, resulting in changes to the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients [Phase 3]
A Phase 3 trial evaluating nilotinib with or without pegylated interferon as first-line therapy for chronic-phase chronic myeloid leukemia h…
-
CLINICAL_TRIALS other · 2025-10-02Clinical Trial Update: Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia [NA]
Clinical trial update noting completion of a study evaluating Gleevec (imatinib) as maintenance therapy after cytogenetic response with nilo…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: What is the Impact of TKI on Thyroid Function in CML Patients?
A clinical trial is investigating whether tyrosine kinase inhibitors used for chronic myeloid leukemia affect thyroid function. The study is…
-
FDA approval · 2025-09-30FDA Approved: DASATINIB — Supplemental Application (Dr.Reddys Laboratories Inc)
The FDA has approved a supplemental application for dasatinib from Dr. Reddy's Laboratories Inc, authorizing an update to the approval of th…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies [EARLY_Phase 1]
An early-phase trial evaluating Darzalex Faspro (daratumumab and hyaluronidase-fihj) given before desensitization and allogeneic stem cell t…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
A completed clinical trial reported on treatment patterns and outcomes for chronic myeloid leukemia across all lines of therapy.